A retrospective, observational study examining the oral corticosteroid sparing effects of anti-IL5/anti-IL5 receptor treatment after one and two years of treatment in a real-life setting
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Benralizumab (Primary) ; Mepolizumab (Primary) ; Reslizumab (Primary) ; Corticosteroids; Prednisolone
- Indications Asthma; Eosinophilia
- Focus Therapeutic Use
Most Recent Events
- 09 Dec 2020 New trial record
- 27 Nov 2020 Primary endpoint (proportion of patients receiving daily OCS after one and two years of anti-IL5/anti-IL5 receptor treatment.) has been met as per results published in the Respiratory Medicine
- 27 Nov 2020 Results published in the Respiratory Medicine